Login Register Cart 0
Generic placeholder image

Infectious Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5265
ISSN (Online): 2212-3989

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Systematic Review Article

Comparison of Omicron and Delta Variants of SARS-CoV-2: A Systematic Review of Current Evidence

Author(s): SeyedAhmad SeyedAlinaghi, Amir Masoud Afsahi, Pegah Mirzapour, Arian Afzalian, Ramin Shahidi, Mohsen Dashti, Afsaneh Ghasemzadeh, Parinaz Paranjkhoo, Zahra Parsaei, Ava Pashaei, Parsa Mohammadi, Mohammad Sadeq Najafi, Sona Mahrokhi, Parisa Matini, Ali Moradi, Amirali Karimi, Solaiman Afroughi, Esmaeil Mehraeen* and Omid Dadras

Volume 24, Issue 7, 2024

Published on: 05 March, 2024

Article ID: e050324227686 Pages: 37

DOI: 10.2174/0118715265279242240216114548

Price: $65

Abstract

Introduction: Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) caused the outbreak of coronavirus disease 2019 (COVID-19) in late 2019 in Wuhan, China. In early 2020, the disease spread rapidly around the world. Since the pandemic, SARS-CoV-2 has evolved dramatically into a wide variety of variants endowed with devastating properties. As of March 6, 2022, five SARS-CoV-2 variants of concern, including Alpha, Beta, Gamma, Delta, and Omicron strains have been identified. Due to the crucial importance of understanding the differences between the Omicron and Delta variants, this systematic review was conducted.

Methods: This systematic review investigated new variants of Omicron SARS-CoV-2 based on current studies. Online databases were searched for English articles as of January 03, 2023. Selection of publications was a two-step process of title/abstract and full-text assessment against eligibility criteria. The relevant data from the included articles were systematically collected and organized in a designed table for analysis. To ensure the quality of the review, the PRISMA checklist and Newcastle- Ottawa Scale (NOS) of quality assessment were utilized.

Results: The data extracted from 58 articles were analyzed, including 10003 pieces of evidence. Lower risk of hospitalization, ICU admission, and mortality after vaccination were reported in the Omicron variant compared to the Delta variant. Additionally, the Delta variant led to more severe clinical symptoms in comparison to the Omicron variant.

Conclusion: The Omicron variant of SARS-CoV-2 results in less severe disease outcomes as compared to Delta. Nevertheless, it remains crucial to maintain ongoing monitoring, implement containment measures, and adapt vaccination protocols to effectively address the evolving variants.

[1]
Mehraeen E, Najafi Z, Hayati B, et al. Current treatments and therapeutic options for COVID-19 patients: A systematic review. Infect Disord Drug Targets 2022; 22(1): e260721194968.
[http://dx.doi.org/10.2174/1871526521666210726150435] [PMID: 34313204]
[2]
Mehraeen E, Oliaei S, SeyedAlinaghi S, et al. COVID-19 in pediatrics: A systematic review of current knowledge and practice. Infect Disord Drug Targets 2022; 22(5): e290921196908.
[http://dx.doi.org/10.2174/1871526521666210929121705] [PMID: 34587889]
[3]
Abebe EC, Dejenie TA, Shiferaw MY, Malik T. The newly emerged COVID-19 disease: A systemic review. Virol J 2020; 17(1): 96.
[http://dx.doi.org/10.1186/s12985-020-01363-5] [PMID: 32641059]
[4]
Dash DP, Sethi N, Dash AK. Infectious disease, human capital, and the BRICS economy in the time of COVID-19. MethodsX 2021; 8: 101202.
[http://dx.doi.org/10.1016/j.mex.2020.101202] [PMID: 33996518]
[5]
Khurshid A, Khan K. How COVID-19 shock will drive the economy and climate? A data-driven approach to model and forecast. Environ Sci Pollut Res Int 2021; 28(3): 2948-58.
[http://dx.doi.org/10.1007/s11356-020-09734-9] [PMID: 32897471]
[6]
Lim WM, To WM. The economic impact of a global pandemic on the tourism economy: the case of COVID-19 and Macao’s destination- and gambling-dependent economy. Curr Issues Tour 2022; 25(8): 1258-69.
[http://dx.doi.org/10.1080/13683500.2021.1910218]
[7]
Pham TD, Dwyer L, Su JJ, Ngo T. COVID-19 impacts of inbound tourism on Australian economy. Ann Tour Res 2021; 88: 103179.
[http://dx.doi.org/10.1016/j.annals.2021.103179] [PMID: 36540369]
[8]
Sandmann FG, Davies NG, Vassall A, et al. The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: A transmission model-based future scenario analysis and economic evaluation. Lancet Infect Dis 2021; 21(7): 962-74.
[http://dx.doi.org/10.1016/S1473-3099(21)00079-7] [PMID: 33743846]
[9]
Seyed Alinaghi S, Karimi A, Barzegary A, Masmoudi A. Mucormycosis infection in patients with COVID-19. Syst Rev 2022; 5(2): e529.
[10]
Ben Hassen H, Elaoud A, Ben Salah N, Masmoudi A. A SIR-Poisson model for COVID-19: Evolution and transmission inference in the Maghreb central regions. Arab J Sci Eng 2021; 46(1): 93-102.
[http://dx.doi.org/10.1007/s13369-020-04792-0] [PMID: 32837814]
[11]
Sixt T, Moretto F, Devilliers H, et al. The usefulness of NEWS2 at day 7 of hospitalization in predicting COVID-19 evolution and as an early endpoint in therapeutic trials. J Infect 2021; 82(2): 282-327.
[http://dx.doi.org/10.1016/j.jinf.2020.09.034] [PMID: 32998039]
[12]
van Oosterhout C, et al. COVID-19 evolution during the pandemic–Implications of new SARS-CoV-2 variants on disease control and public health policies. Taylor & Francis 2021; pp. 507-8.
[13]
Veronese S, Sbarbati A. Chemosensory systems in COVID-19: Evolution of scientific research. ACS Chem Neurosci 2021; 12(5): 813-24.
[http://dx.doi.org/10.1021/acschemneuro.0c00788] [PMID: 33559466]
[14]
Tracking SARS-CoV-2 Variants. Available from: https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/ (Accessed on 6 March 2022).
[15]
Mehraeen E, SeyedAlinaghi S, Karimi A. The post‐Omicron situation: The end of the pandemic or a bigger challenge? J Med Virol 2022; 94(8): 3501-2.
[http://dx.doi.org/10.1002/jmv.27765] [PMID: 35388514]
[16]
Mahase E. Delta variant: What is happening with transmission, hospital admissions, and restrictions?. British Medical Journal Publishing Group 2021.
[17]
Ravisankar M, Alexandar S, Senthil Kumar R, Jakkan K. A comprehensive review on Covid-19 Delta variant. Intern J Pharma Clin Res 2021; 5(2): 83-5. [IJPCR].
[18]
del Rio C, Malani PN, Omer SB. Confronting the delta variant of SARS-CoV-2, summer 2021. JAMA 2021; 326(11): 1001-2.
[http://dx.doi.org/10.1001/jama.2021.14811] [PMID: 34406361]
[19]
Liu Y, Rocklöv J. The reproductive number of the Delta variant of SARS-CoV-2 is far higher compared to the ancestral SARS-CoV-2 virus. J Travel Med 2021; 28(7): taab124.
[http://dx.doi.org/10.1093/jtm/taab124] [PMID: 34369565]
[20]
Twohig KA, Nyberg T, Zaidi A, et al. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. Lancet Infect Dis 2022; 22(1): 35-42.
[http://dx.doi.org/10.1016/S1473-3099(21)00475-8] [PMID: 34461056]
[21]
Blakely T, et al. The probability of the 6‐week lockdown in Victoria (commencing 9 July 2020) achieving elimination of community transmission of SARS‐CoV‐2. Med J Australia 2020; 213(8): 349-51.
[22]
Mehraeen E, Dadras O, Afsahi AM, et al. Vaccines for COVID-19: A systematic review of feasibility and effectiveness. Infect Disord Drug Targets 2022; 22(2): e230921196758.
[http://dx.doi.org/10.2174/1871526521666210923144837] [PMID: 34554905]
[23]
Rao S, Singh M. The newly detected B. 1.1. 529 (Omicron) variant of SARS-CoV-2 with multiple mutations: Implications for transmission, diagnostics, therapeutics, and immune evasion. DHR Proceedings, 2021; 1(5): 7-10.
[24]
Venkatakrishnan AJ, Anand P, Patrick J, et al. Omicron variant of SARS-CoV-2 harbors a unique insertion mutation of putative viral or human genomic origin. Medicine 2021.
[http://dx.doi.org/10.31219/osf.io/f7txy]
[25]
Romagnoli A, D’Agostino M, Pavoni E, et al. SARS-CoV-2 multi-variant rapid detector based on graphene transistor functionalized with an engineered dimeric ACE2 receptor. Nano Today 2023; 48: 101729.
[http://dx.doi.org/10.1016/j.nantod.2022.101729] [PMID: 36536857]
[26]
Rexha J, Perta N, Roscioni A, et al. Unlocking the potential of field effect transistor (FET) biosensors: A perspective on methodological advances in computational and molecular biology. Advanced Sensor Research 2023; 2(11): 2300053.
[http://dx.doi.org/10.1002/adsr.202300053]
[27]
Adhikari EH, MacDonald L, SoRelle JA, Morse J, Pruszynski J, Spong CY. COVID-19 cases and disease severity in pregnancy and neonatal positivity associated with delta (B.1.617.2) and omicron (B.1.1.529) variant predominance. JAMA 2022; 327(15): 1500-2.
[http://dx.doi.org/10.1001/jama.2022.4356] [PMID: 35325015]
[28]
Akaishi T, Ishii T. Coronavirus disease 2019 transmission and symptoms in young children during the severe acute respiratory syndrome coronavirus 2 Delta variant and Omicron variant outbreaks. J Int Med Res 2022; 50(5)
[http://dx.doi.org/10.1177/03000605221102079] [PMID: 35619217]
[29]
Auvigne V, Vaux S, Strat YL, et al. Severe hospital events following symptomatic infection with Sars-CoV-2 Omicron and Delta variants in France, December 2021–January 2022: A retrospective, population-based, matched cohort study. EClinicalMedicine 2022; 48: 101455.
[http://dx.doi.org/10.1016/j.eclinm.2022.101455] [PMID: 35611065]
[30]
Bager P, Wohlfahrt J, Bhatt S, et al. Risk of hospitalisation associated with infection with SARS-CoV-2 omicron variant versus delta variant in Denmark: An observational cohort study. Lancet Infect Dis 2022; 22(7): 967-76.
[http://dx.doi.org/10.1016/S1473-3099(22)00154-2] [PMID: 35468331]
[31]
Bouzid D, Visseaux B, Kassasseya C, et al. Comparison of patients infected with delta versus omicron COVID-19 variants presenting to paris emergency departments. Ann Intern Med 2022; 175(6): 831-7.
[http://dx.doi.org/10.7326/M22-0308] [PMID: 35286147]
[32]
Butt AA, Dargham SR, Tang P, et al. COVID-19 disease severity in persons infected with the Omicron variant compared with the Delta variant in Qatar. J Glob Health 2022; 12: 05032.
[http://dx.doi.org/10.7189/jogh.12.05032] [PMID: 35788085]
[33]
Chaguza C, Coppi A, Earnest R, et al. Rapid emergence of SARS-CoV-2 Omicron variant is associated with an infection advantage over Delta in vaccinated persons. Med 2022; 3(5): 325-334.e4.
[http://dx.doi.org/10.1016/j.medj.2022.03.010] [PMID: 35399324]
[34]
Corriero A, Ribezzi M, Mele F, et al. COVID-19 variants in critically ill patients: A comparison of the delta and omicron variant profiles. Infect Dis Rep 2022; 14(3): 492-500.
[http://dx.doi.org/10.3390/idr14030052] [PMID: 35735762]
[35]
Eggink D, Andeweg SP, Vennema H, et al. Increased risk of infection with SARS-CoV-2 Omicron BA.1 compared with Delta in vaccinated and previously infected individuals, the Netherlands, 22 November 2021 to 19 January 2022. Euro Surveill 2022; 27(4): 2101196.
[http://dx.doi.org/10.2807/1560-7917.ES.2022.27.4.2101196] [PMID: 35086609]
[36]
Feng S, Ali MS, Evdokimova M, et al. Sequencing during times of change: Evaluating sars-cov-2 clinical samples during the transition from the delta to omicron wave. Viruses 2022; 14(7): 1408.
[http://dx.doi.org/10.3390/v14071408] [PMID: 35891388]
[37]
Ferdinands JM, Rao S, Dixon BE, et al. Waning 2-dose and 3-dose effectiveness of mrna vaccines against covid-19–associated emergency department and urgent care encounters and hospitalizations among adults during periods of delta and omicron variant predominance: Vision network, 10 states, August 2021–January 2022. MMWR Morb Mortal Wkly Rep 2022; 71(7): 255-63.
[http://dx.doi.org/10.15585/mmwr.mm7107e2] [PMID: 35176007]
[38]
Granata V, Fusco R, Villanacci A, et al. Imaging Severity COVID-19 assessment in vaccinated and unvaccinated patients: Comparison of the different variants in a high volume italian reference center. J Pers Med 2022; 12(6): 955.
[http://dx.doi.org/10.3390/jpm12060955] [PMID: 35743740]
[39]
Iuliano AD, Brunkard JM, Boehmer TK, et al. Trends in disease severity and health care utilization during the early omicron variant period compared with previous SARS-CoV-2 high transmission periods — united states, December 2020–January 2022. MMWR Morb Mortal Wkly Rep 2022; 71(4): 146-52.
[http://dx.doi.org/10.15585/mmwr.mm7104e4] [PMID: 35085225]
[40]
Johnson AG, Amin AB, Ali AR, et al. COVID-19 incidence and death rates among unvaccinated and fully vaccinated adults with and without booster doses during periods of delta and omicron variant emergence — 25 u.s. jurisdictions, April 4–December 25, 2021. MMWR Morb Mortal Wkly Rep 2022; 71(4): 132-8.
[http://dx.doi.org/10.15585/mmwr.mm7104e2] [PMID: 35085223]
[41]
Kiss Z, Wittmann I, Polivka L, et al. Nationwide effectiveness of first and second SARS-CoV2 booster vaccines during the delta and omicron pandemic waves in hungary (HUN-VE 2 Study). Front Immunol 2022; 13: 905585.
[http://dx.doi.org/10.3389/fimmu.2022.905585] [PMID: 35812442]
[42]
Kodera S, Rashed EA, Hirata A. Estimation of real-world vaccination effectiveness of mRNA COVID-19 vaccines against delta and omicron variants in japan. Vaccines 2022; 10(3): 430.
[http://dx.doi.org/10.3390/vaccines10030430] [PMID: 35335062]
[43]
Lauring AS, Tenforde MW, Chappell JD, et al. Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. BMJ 2022; 376: e069761.
[http://dx.doi.org/10.1136/bmj-2021-069761] [PMID: 35264324]
[44]
Li M, Liu Q, Wu D, et al. Association of COVID-19 vaccination and clinical severity of patients infected with delta or omicron variants: China, May 21, 2021-February 28, 2022. China CDC Wkly 2022; 4(14): 293-7.
[http://dx.doi.org/10.46234/ccdcw2022.074] [PMID: 35433093]
[45]
Magnusson K, Kristoffersen DT, Dell’Isola A, et al. Post-covid medical complaints following infection with SARS-CoV-2 Omicron vs. Delta variants. Nat Commun 2022; 13(1): 7363.
[http://dx.doi.org/10.1038/s41467-022-35240-2]
[46]
Maslo C, Friedland R, Toubkin M, Laubscher A, Akaloo T, Kama B. Characteristics and outcomes of hospitalized patients in south africa during the COVID-19 omicron wave compared with previous waves. JAMA 2022; 327(6): 583-4.
[http://dx.doi.org/10.1001/jama.2021.24868] [PMID: 34967859]
[47]
Mayr FB, Talisa VB, Castro AD, Shaikh OS, Omer SB, Butt AA. COVID-19 disease severity in US Veterans infected during Omicron and Delta variant predominant periods. Nat Commun 2022; 13(1): 3647.
[http://dx.doi.org/10.1038/s41467-022-31402-4] [PMID: 35752687]
[48]
Menni C, Valdes AM, Polidori L, et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: A prospective observational study from the ZOE COVID Study. Lancet 2022; 399(10335): 1618-24.
[http://dx.doi.org/10.1016/S0140-6736(22)00327-0] [PMID: 35397851]
[49]
Modes ME, Directo MP, Melgar M, et al. Clinical characteristics and outcomes among adults hospitalized with laboratory-confirmed sars-cov-2 infection during periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance - One Hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022. MMWR Morb Mortal Wkly Rep 2022; 71(6): 217-23.
[http://dx.doi.org/10.15585/mmwr.mm7106e2] [PMID: 35143466]
[50]
Nielsen KF, Moustsen-Helms IR, Schelde AB, et al. Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha (B.1.1.7), Delta (B.1.617.2) or Omicron (B.1.1.529) dominance: A Danish nationwide study. PLoS Med 2022; 19(11): 1004037.
[51]
Niyomnaitham S, Toh ZQ, Licciardi PV, et al. Immunogenicity of a single dose of BNT162b2, ChAdOx1 nCoV-19, or CoronaVac against SARS-CoV-2 delta and omicron variants among previously infected adults: A randomized trial. J Infect 2022; 85(4): 436-80.
[http://dx.doi.org/10.1016/j.jinf.2022.06.014] [PMID: 35728642]
[52]
Norddahl GL, Melsted P, Gunnarsdottir K, Halldorsson GH, et al. Effect of booster vaccination against Delta and Omicron variants in Iceland. bioRxiv 2022.
[http://dx.doi.org/10.1101/2022.02.26.22271509]
[53]
Nyberg T, Ferguson NM, Nash SG, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: A cohort study. Lancet 2022; 399(10332): 1303-12.
[http://dx.doi.org/10.1016/S0140-6736(22)00462-7] [PMID: 35305296]
[54]
Özüdoğru O, Bahçe YG, Acer Ö. SARS CoV-2 reinfection rate is higher in the Omicron variant than in the Alpha and Delta variants. Ir J Med Sci 2022; 192(2): 751-6.
[PMID: 35711013]
[55]
Pacchiarini N, Sawyer C, Williams C, et al. Epidemiological analysis of the first 1000 cases of SARS‐CoV‐2 lineage BA.1 (B.1.1.529, Omicron) compared with co‐circulating Delta in Wales, UK. Influenza Other Respir Viruses 2022; 16(6): 986-93.
[http://dx.doi.org/10.1111/irv.13021] [PMID: 35822273]
[56]
Rovida F, Esposito GL, Rissone M, et al. Characteristics and outcomes of vaccinated and nonvaccinated patients hospitalized in a single Italian hub for COVID-19 during the Delta and Omicron waves in Northern Italy. Int J Infect Dis 2022; 122: 420-6.
[http://dx.doi.org/10.1016/j.ijid.2022.06.028] [PMID: 35750265]
[57]
Seasely AR, Blanchard CT, Arora N, et al. Maternal and perinatal outcomes associated With the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta (B.1.617.2) variant. Obstet Gynecol 2021; 138(6): 842-4.
[http://dx.doi.org/10.1097/AOG.0000000000004607] [PMID: 34592747]
[58]
Sentis C, Billaud G, Bal A, et al. SARS-CoV-2 Omicron Variant, Lineage BA.1, Is Associated with Lower Viral Load in Nasopharyngeal Samples Compared to Delta Variant. Viruses-BASEL 2022; 14(5): 919.
[PMID: 35632661] [PMCID: PMC9144383]
[59]
Servellita V, Syed AM, Morris MK, et al. Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants. Cell 2022; 185(9): 1539-1548.e5.
[http://dx.doi.org/10.1016/j.cell.2022.03.019] [PMID: 35429436]
[60]
Sheikh A, Kerr S, Woolhouse M, et al. Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): A national cohort study with nested test-negative design. Lancet Infect Dis 2022; 22(7): 959-66.
[http://dx.doi.org/10.1016/S1473-3099(22)00141-4] [PMID: 35468332]
[61]
Shetty A, Chatterjee G, Rajpal S, et al. Genomic analysis of AZD1222 (ChAdOx1) vaccine breakthrough infections in the City of Mumbai. Int J Clin Pract 2022; 2022: 1-9.
[http://dx.doi.org/10.1155/2022/2449068] [PMID: 35685574]
[62]
Sofonea MT, Roquebert B, Foulongne V, et al. Analyzing and modeling the spread of SARS-CoV-2 Omicron Lineages BA.1 and BA.2, France, September 2021–February 2022. Emerg Infect Dis 2022; 28(7): 1355-65.
[http://dx.doi.org/10.3201/eid2807.220033] [PMID: 35642476]
[63]
Sormani MP, Schiavetti I, Inglese M, et al. Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy. EBioMedicine 2022; 80: 104042.
[http://dx.doi.org/10.1016/j.ebiom.2022.104042] [PMID: 35526306]
[64]
Stålcrantz J, Kristoffersen AB, Bøås H, et al. Milder disease trajectory among COVID-19 patients hospitalised with the SARS-CoV-2 Omicron variant compared with the Delta variant in Norway. Scand J Public Health 2022; 50(6): 676-82.
[PMID: 35799474]
[65]
Stowe J, Andrews N, Kirsebom F, et al. Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation: Test negative case-control study. Nat Commun 2022; 13(1): 5736.
[http://dx.doi.org/10.1038/s41467-022-33378-7]
[66]
Suah JL, Tng BH, Tok PSK, et al. Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infection. Emerg Microbes Infect 2022; 11(1): 1343-5.
[http://dx.doi.org/10.1080/22221751.2022.2072773] [PMID: 35499301]
[67]
Suarez Castillo M, Khaoua H, Courtejoie N. Vaccine-induced and naturally-acquired protection against Omicron and Delta symptomatic infection and severe COVID-19 outcomes, France, December 2021 to January 2022. Euro Surveill 2022; 27(16): 2200250.
[http://dx.doi.org/10.2807/1560-7917.ES.2022.27.16.2200250] [PMID: 35451363]
[68]
Tanaka H, Ogata T, Shibata T, et al. Shorter incubation period among COVID-19 Cases with the BA.1 Omicron Variant. Int J Environ Res Public Health 2022; 19(10): 6330.
[http://dx.doi.org/10.3390/ijerph19106330] [PMID: 35627870]
[69]
Tartof SY, Slezak JM, Puzniak L, et al. Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: A test-negative case–control study. Lancet Respir Med 2022; 10(7): 689-99.
[http://dx.doi.org/10.1016/S2213-2600(22)00101-1] [PMID: 35468336]
[70]
Taylor CA, Whitaker M, Anglin O, et al. COVID-19–associated hospitalizations among adults during SARS-CoV-2 delta and omicron variant predominance, by race/ethnicity and vaccination status — COVID-NET, 14 States, July 2021–January 2022. MMWR Morb Mortal Wkly Rep 2022; 71(12): 466-73.
[http://dx.doi.org/10.15585/mmwr.mm7112e2] [PMID: 35324880]
[71]
Taytard J, Prevost B, Schnuriger A, et al. SARS-CoV-2 B.1.1.529 (Omicron) variant causes an unprecedented surge in children hospitalizations and distinct clinical presentation compared to the SARS-CoV-2 B.1.617.2 (Delta) variant. Front Pediatr 2022; 10: 932170.
[http://dx.doi.org/10.3389/fped.2022.932170] [PMID: 35832582]
[72]
Tekin AB, Yassa M, Birol İlter P, et al. COVID-19 related maternal mortality cases in associated with Delta and Omicron waves and the role of lung ultrasound. J Turk Soc Obs Gyn 2022; 19(2): 88-97.
[http://dx.doi.org/10.4274/tjod.galenos.2022.36937] [PMID: 35770508]
[73]
Thompson MG, Natarajan K, Irving SA, et al. Effectiveness of a third dose of mRNA vaccines against COVID-19–Associated emergency department and urgent care encounters and hospitalizations among adults during periods of delta and omicron variant predominance — VISION Network, 10 States, August 2021–January 2022. MMWR Morb Mortal Wkly Rep 2022; 71(4): 139-45.
[http://dx.doi.org/10.15585/mmwr.mm7104e3] [PMID: 35085224]
[74]
Tobin RJ, Wood JG, Jayasundara D, et al. Hospital length of stay in a mixed omicron and delta epidemic in New South Wales. In: BMC Infect Dis Australia 2022; 23(1): 28.
[http://dx.doi.org/10.1101/2022.03.16.22271361]
[75]
Tseng HF, Ackerson BK, Luo Y, et al. Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. Nat Med 2022; 28(5): 1063-71.
[http://dx.doi.org/10.1038/s41591-022-01753-y] [PMID: 35189624]
[76]
Van Goethem N, Chung PYJ, Meurisse M, et al. Clinical severity of SARS-CoV-2 omicron variant compared with delta among hospitalized COVID-19 patients in belgium during autumn and winter season 2021–2022. Viruses 2022; 14(6): 1297.
[http://dx.doi.org/10.3390/v14061297] [PMID: 35746768]
[77]
Veneti L, Bøås H, Bråthen Kristoffersen A, et al. Reduced risk of hospitalisation among reported COVID-19 cases infected with the SARS-CoV-2 Omicron BA.1 variant compared with the Delta variant, Norway, December 2021 to January 2022. Euro Surveill 2022; 27(4): 2200077.
[http://dx.doi.org/10.2807/1560-7917.ES.2022.27.4.2200077] [PMID: 35086614]
[78]
Veneti L, Berild JD, Watle SV, et al. Effectiveness of BNT162b2 vaccine against SARS-CoV-2 Delta and Omicron infection in adolescents, Norway, August 2021 to January 2022. Int J Infect Dis 2022; 130: 182-8.
[79]
Vihta KD, Pouwels KB, Peto TE, et al. Omicron-associated changes in SARS-CoV-2 symptoms in the United Kingdom. medRxiv 2022.
[http://dx.doi.org/10.1101/2022.01.18.22269082]
[80]
Visconti A, Murray B, Rossi N, et al. Cutaneous manifestations of SARS-CoV-2 infection during the Delta and Omicron waves in 348 691 UK users of the UK ZOE COVID Study app. Br J Dermatol 2022; 187(6): 900-8.
[http://dx.doi.org/10.1111/bjd.21784] [PMID: 35869671]
[81]
Sievers C, Zacher B, Ullrich A, et al. SARS-CoV-2 Omicron variants BA.1 and BA.2 both show similarly reduced disease severity of COVID-19 compared to Delta, Germany, 2021 to 2022. Euro Surveill 2022; 27(22): 2200396.
[http://dx.doi.org/10.2807/1560-7917.ES.2022.27.22.2200396] [PMID: 35656831]
[82]
Skarbinski J, Wood MS, Chervo TC, et al. Risk of severe clinical outcomes among persons with SARS-CoV-2 infection with differing levels of vaccination during widespread Omicron (B.1.1.529) and Delta (B.1.617.2) variant circulation in Northern California: A retrospective cohort study. Lancet Regional Health - Americas 2022; 12: 100297.
[http://dx.doi.org/10.1016/j.lana.2022.100297] [PMID: 35756977]
[83]
Hu T, Zhang M, Deng A, et al. Comparison of omicron and delta variant infection COVID-19 Cases: Guangdong province, China, 2022. China CDC Wkly 2022; 4(18): 385-8.
[PMID: 35686204]
[84]
Birol Ilter P, Prasad S, Mutlu MA, et al. Maternal and perinatal outcomes of SARS‐CoV ‐2 infection in unvaccinated pregnancies during Delta and Omicron waves. Ultrasound Obstet Gynecol 2022; 60(1): 96-102.
[http://dx.doi.org/10.1002/uog.24916] [PMID: 35441407]
[85]
WHO Coronavirus (COVID-19) Dashboard. 2023. Available from: https://data.who.int/dashboards/covid19/cases?n=c
[86]
Hyams C, Challen R, Marlow R, et al. Severity of Omicron (B.1.1.529) and Delta (B.1.617.2) SARS-CoV-2 infection among hospitalised adults: A prospective cohort study in Bristol, United Kingdom. Lancet Reg Health Eur 2023; 25: 100556.
[http://dx.doi.org/10.1016/j.lanepe.2022.100556] [PMID: 36530491]
[87]
Leiner J, Pellissier V, Hohenstein S, et al. Characteristics and outcomes of COVID-19 patients during B.1.1.529 (Omicron) dominance compared to B.1.617.2 (Delta) in 89 German hospitals. BMC Infect Dis 2022; 22(1): 802.
[http://dx.doi.org/10.1186/s12879-022-07781-w] [PMID: 36303111]
[88]
Ding K, Jiang W, Xiong C, Lei M. Turning point: A new global COVID‐19 wave or a signal of the beginning of the end of the global COVID‐19 pandemic? Immun Inflamm Dis 2022; 10(4): e606.
[http://dx.doi.org/10.1002/iid3.606] [PMID: 35349754]
[89]
Araf Y, Akter F, Tang Y, et al. Omicron variant of SARS‐CoV‐2: Genomics, transmissibility, and responses to current COVID‐19 vaccines. J Med Virol 2022; 94(5): 1825-32.
[http://dx.doi.org/10.1002/jmv.27588] [PMID: 35023191]
[90]
Willett BJ, Grove J, MacLean OA, et al. SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway. Nat Microbiol 2022; 7(8): 1161-79.
[http://dx.doi.org/10.1038/s41564-022-01143-7] [PMID: 35798890]
[91]
Hoffmann M, Krüger N, Schulz S, et al. The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic. Cell 2022; 185(3): 447-56.
[92]
Du M, Ma Y, Deng J, Liu M, Liu J. Comparison of long COVID-19 Caused by different SARS-CoV-2 strains: A systematic review and meta-analysis. Int J Environ Res Public Health 2022; 19(23): 16010.
[http://dx.doi.org/10.3390/ijerph192316010] [PMID: 36498103]
[93]
Kow CS, Ramachandram DS, Hasan SS. The risk of mortality and severe illness in patients infected with the omicron variant relative to delta variant of SARS-CoV-2: A systematic review and meta-analysis. Irish J Med Sci 2023; 1-8.
[94]
Ward IL, Bermingham C, Ayoubkhani D, et al. Risk of covid-19 related deaths for SARS-CoV-2 omicron (B.1.1.529) compared with delta (B.1.617.2): Retrospective cohort study. BMJ 2022; 378: e070695.
[http://dx.doi.org/10.1136/bmj-2022-070695] [PMID: 35918098]
[95]
Accorsi EK, Britton A, Fleming-Dutra KE, et al. Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 Omicron and Delta variants. JAMA 2022; 327(7): 639-51.
[http://dx.doi.org/10.1001/jama.2022.0470] [PMID: 35060999]
[96]
SeyedAlinaghi S, Karimi A, Pashaei Z, et al. Safety and adverse events related to COVID-19 mRNA vaccines; a systematic review. Arch Acad Emerg Med 2022; 10(1): e41.
[PMID: 35765616]
[97]
Christensen PA, Olsen RJ, Long SW, et al. Signals of significantly increased vaccine breakthrough, decreased hospitalization rates, and less severe disease in patients with coronavirus disease 2019 caused by the omicron variant of severe acute respiratory syndrome coronavirus 2 in Houston, Texas. Am J Pathol 2022; 192(4): 642-52.
[http://dx.doi.org/10.1016/j.ajpath.2022.01.007] [PMID: 35123975]
[98]
Esper FP, Adhikari TM, Tu ZJ, et al. Alpha to Omicron: Disease severity and clinical outcomes of major SARS-CoV-2 variants. J Infect Dis 2023; 227(3): 344-52.
[http://dx.doi.org/10.1093/infdis/jiac411] [PMID: 36214810]
[99]
Duong BV, Larpruenrudee P, Fang T, et al. Is the SARS CoV-2 omicron variant deadlier and more transmissible than delta variant? Int J Environ Res Public Health 2022; 19(8): 4586.
[http://dx.doi.org/10.3390/ijerph19084586] [PMID: 35457468]
[100]
Mehraeen E, Pashaei Z, Akhtaran FK, et al. Estimating methods of the undetected infections in the COVID-19 outbreak: A systematic review. Infect Disord Drug Targets 2023; 23(4): 19-36.
[101]
SeyedAlinaghi S, Karimi A, Afsahi AM, et al. The effectiveness of face masks in preventing covid-19 transmission: A systematic review. Infect Disord Drug Targets 2023; 23(8): 19-29.
[102]
Mehraeen E, Karimi A, Mirghaderi P, et al. The Impact of COVID-19 Pandemic on the Levels of Physical Activity: A Systematic Review. Infect Disord Drug Targets 2023; 23(4): e200123212975.
[http://dx.doi.org/10.2174/1871526523666230120143118] [PMID: 36683317]
[103]
SeyedAlinaghi S, Mirzapour P, Dadras O, et al. Characterization of SARS-CoV-2 different variants and related morbidity and mortality: a systematic review. Eur J Med Res 2021 Jun 8; 26(1): 51.
[http://dx.doi.org/10.1186/s8-00524-021-40001] [PMID: 34103090] [PMCID: PMC8185313]
[104]
(a) Mehraeen E, Salehi MA, Behnezhad F, Moghaddam HR, Seyed-Alinaghi S. Transmission Modes of COVID-19: A Systematic Review. Infect Disord Drug Targets 2021; 21(6): e170721187995.
[http://dx.doi.org/10.2174/1871526520666201116095934] [PMID: 33200716];
(b) Mehraeen E, Hayati B, Saeidi S, Heydari M, Seyedalinaghi S. Self-Care Instructions for People Not Requiring Hospitalization for Coronavirus Disease 2019 (COVID-19). Arch Clin Infect Dis 2020; 15(COVID-19): e102978.
[http://dx.doi.org/10.5812/archcid.102978]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy